Cantor Fitzgerald Reiterates TherapeuticsMD (TXMD) at Overweight, "TXMD's Opportunity to Become Leading Women's Healthcare Company Remains Underappreciated"
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $5.00 price target on TherapeuticsMD (NASDAQ: TXMD), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
